ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
126.134,94
-0,61%
S&P 500
6.040,53
-0,50%
US Dollar vs BRL
5,842
0,00%
Bitcoin
98.850,00
-1,81%
Brent Oil
76,385
0,00%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. ImmunoPrecise Antibodies Ltd (IPA)

  7. ImmunoPrecise Antibodies Ltd (IPA) Notícias

IPA

ImmunoPrecise Antibodies (IPA)

ImmunoPrecise Antibodies Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IPA
DataHoraFonteTítuloCódigoCompanhia
27/01/202519:16Business WireImmunoPrecise Antibodies (IPA) annonce la réalisation d'un placement d'actions sur le marché et la conversion complète de la débenture de YorkvilleNASDAQ:IPAImmunoPrecise Antibodies Ltd
27/01/202512:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
27/01/202510:01Business WireImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville DebentureNASDAQ:IPAImmunoPrecise Antibodies Ltd
24/01/202515:58Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
22/01/202516:19Business WireIPA (ImmunoPrecise Antibodies), pionnier des thérapies GLP-1 conçues par l'IA : Un nouveau chapitre potentiel en matière de traitement du diabèteNASDAQ:IPAImmunoPrecise Antibodies Ltd
22/01/202509:02Business WireIPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes TreatmentNASDAQ:IPAImmunoPrecise Antibodies Ltd
17/01/202523:25Business WireImmunoPrecise Antibodies redéfinit sa stratégie de pipeline en faisant appel à l'IA et à l'innovation basée sur les principes premiers pour la découverte de médicamentsNASDAQ:IPAImmunoPrecise Antibodies Ltd
17/01/202510:01Business WireImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles InnovationNASDAQ:IPAImmunoPrecise Antibodies Ltd
01/01/202509:44Business WireL'IPA annonce la démission de sa directrice financièreNASDAQ:IPAImmunoPrecise Antibodies Ltd
31/12/202421:56Business WireIPA Announces Resignation of Chief Financial OfficerNASDAQ:IPAImmunoPrecise Antibodies Ltd
23/12/202414:02Business WireImmunoPrecise Antibodies (IPA) démontre une solide confiance du marché avec des achats d'actions par des membres de la directionNASDAQ:IPAImmunoPrecise Antibodies Ltd
23/12/202410:30Business WireImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share PurchasesNASDAQ:IPAImmunoPrecise Antibodies Ltd
19/12/202414:56Business WirePrésentation de l'IPA à la Microcap Conference 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
19/12/202410:00Business WireIPA to Present at The Microcap Conference 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
11/12/202408:34Business WireImmunoPrecise Antibodies (IPA) publie ses résultats financiers et les faits saillants de ses activités du deuxième trimestre de l’exercice 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
10/12/202410:37Edgar (US Regulatory)Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
10/12/202410:30Business WireImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025NASDAQ:IPAImmunoPrecise Antibodies Ltd
05/12/202408:23Business WireL'IPA participera à la prochaine conférence de découverte en tête-à-tête d'investisseurs organisée par The Benchmark CompanyNASDAQ:IPAImmunoPrecise Antibodies Ltd
04/12/202410:00Business WireIPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor ConferenceNASDAQ:IPAImmunoPrecise Antibodies Ltd
04/12/202401:08Business WireL'IPA publiera ses résultats financiers et les faits importants de son activité récente pour le deuxième trimestre de l'exercice 2025 le 10 décembre 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
03/12/202410:30Business WireIPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
14/11/202417:13Business WireUne percée commerciale de 20 milliards de dollars : l'IPA est pionnière dans le développement d'anticorps à fort impact pour les thérapies anticancéreuses ADC de nouvelle générationNASDAQ:IPAImmunoPrecise Antibodies Ltd
13/11/202411:00Business Wire$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer TherapiesNASDAQ:IPAImmunoPrecise Antibodies Ltd
05/11/202403:53Business WireImmunoPrecise annonce son TECHDAY, un événement dédié à l'innovation de pointe en matière d'IA et de produits biologiquesNASDAQ:IPAImmunoPrecise Antibodies Ltd
04/11/202410:01Business WireImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics InnovationNASDAQ:IPAImmunoPrecise Antibodies Ltd
28/10/202422:59Business WireImmunoPrecise soutient la recherche antivieillissement dans le cadre d'une étude de la Mayo Clinic et s'apprête à entrer dans un marché de 81 milliards de dollars avec une technologie d'IANASDAQ:IPAImmunoPrecise Antibodies Ltd
28/10/202408:30Business WireImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI TechnologyNASDAQ:IPAImmunoPrecise Antibodies Ltd
23/10/202407:11Business WireImmunoPrecise Antibodies participera à l'AI Driven Drug Discovery Summit USA 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
21/10/202410:00Business WireImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
10/10/202420:50Business WireImmunoPrecise Antibodies célèbre le prix Nobel de chimie et les avancées dans la conception de protéines optimisée par l'IANASDAQ:IPAImmunoPrecise Antibodies Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:IPA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
FICT3
Fictor Alimentos ON
BOV
AGXY3
Agrogalaxy Participacoes ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
AZEV4
AZEVEDO PN
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios